SPARSE DRUG CONCENTRATION DATA ANALYSIS USING A POPULATION APPROACH: A VALUABLE TOOL IN CLINICAL PHARMACOLOGY
1. Drug concentration or pharmacological effect data collected from patients during therapy or as part of a Phase III or post-marketing study are generally sparse (i.e. one or a few observations per patient) in nature.2. The population approach to analysing sparse drug concentration data provides a...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
McLachlan, Andrew J. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|
| Erschienen: |
Oxford, UK: Blackwell Publishing Ltd ; 1996 |
|---|
| Schlagwörter: |
|---|
| Umfang: |
Online-Ressource |
|---|
| Reproduktion: |
2007 ; Blackwell Publishing Journal Backfiles 1879-2005 |
|---|---|
| Übergeordnetes Werk: |
In: Clinical and experimental pharmacology and physiology - Oxford [u.a.] : Wiley-Blackwell, 1974, 23(1996), 10/11, Seite 0 |
| Übergeordnetes Werk: |
volume:23 ; year:1996 ; number:10/11 ; pages:0 |
| Links: |
|---|
| DOI / URN: |
10.1111/j.1440-1681.1996.tb01157.x |
|---|
| Katalog-ID: |
NLEJ238597326 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLEJ238597326 | ||
| 003 | DE-627 | ||
| 005 | 20230505184105.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 120417s1996 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1111/j.1440-1681.1996.tb01157.x |2 doi | |
| 035 | |a (DE-627)NLEJ238597326 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 100 | 1 | |a McLachlan, Andrew J. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a SPARSE DRUG CONCENTRATION DATA ANALYSIS USING A POPULATION APPROACH: A VALUABLE TOOL IN CLINICAL PHARMACOLOGY |
| 264 | 1 | |a Oxford, UK |b Blackwell Publishing Ltd |c 1996 | |
| 300 | |a Online-Ressource | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a 1. Drug concentration or pharmacological effect data collected from patients during therapy or as part of a Phase III or post-marketing study are generally sparse (i.e. one or a few observations per patient) in nature.2. The population approach to analysing sparse drug concentration data provides a valuable tool for obtaining information about the pharmacokinetics of drugs in special patient groups (neonates, aged or critically ill), the importance of drug interactions in the clinic (using routinely collected blood concentration data) and for conducting a ‘pharmacokinetic screen’ in patients during early phase efficacy trials.3. Using a population approach to analyse drug concentration-time data collected from patients during therapy or during an early phase investigation can complement information obtained from traditional pharmacokinetic/dynamic investigations to help gain a further insight into the factors that influence dosing guidelines. | ||
| 533 | |d 2007 |f Blackwell Publishing Journal Backfiles 1879-2005 |7 |2007|||||||||| | ||
| 650 | 4 | |a cyclosporin | |
| 773 | 0 | 8 | |i In |t Clinical and experimental pharmacology and physiology |d Oxford [u.a.] : Wiley-Blackwell, 1974 |g 23(1996), 10/11, Seite 0 |h Online-Ressource |w (DE-627)NLEJ243927150 |w (DE-600)2020033-X |x 1440-1681 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:1996 |g number:10/11 |g pages:0 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/j.1440-1681.1996.tb01157.x |q text/html |x Verlag |z Deutschlandweit zugänglich |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a ZDB-1-DJB | ||
| 912 | |a GBV_NL_ARTICLE | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 1996 |e 10/11 |h 0 | ||
| author_variant |
a j m aj ajm |
|---|---|
| matchkey_str |
article:14401681:1996----::prergocnrtodtaayiuigppltoapocaaube |
| hierarchy_sort_str |
1996 |
| publishDate |
1996 |
| allfields |
10.1111/j.1440-1681.1996.tb01157.x doi (DE-627)NLEJ238597326 DE-627 ger DE-627 rakwb McLachlan, Andrew J. verfasserin aut SPARSE DRUG CONCENTRATION DATA ANALYSIS USING A POPULATION APPROACH: A VALUABLE TOOL IN CLINICAL PHARMACOLOGY Oxford, UK Blackwell Publishing Ltd 1996 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier 1. Drug concentration or pharmacological effect data collected from patients during therapy or as part of a Phase III or post-marketing study are generally sparse (i.e. one or a few observations per patient) in nature.2. The population approach to analysing sparse drug concentration data provides a valuable tool for obtaining information about the pharmacokinetics of drugs in special patient groups (neonates, aged or critically ill), the importance of drug interactions in the clinic (using routinely collected blood concentration data) and for conducting a ‘pharmacokinetic screen’ in patients during early phase efficacy trials.3. Using a population approach to analyse drug concentration-time data collected from patients during therapy or during an early phase investigation can complement information obtained from traditional pharmacokinetic/dynamic investigations to help gain a further insight into the factors that influence dosing guidelines. 2007 Blackwell Publishing Journal Backfiles 1879-2005 |2007|||||||||| cyclosporin In Clinical and experimental pharmacology and physiology Oxford [u.a.] : Wiley-Blackwell, 1974 23(1996), 10/11, Seite 0 Online-Ressource (DE-627)NLEJ243927150 (DE-600)2020033-X 1440-1681 nnns volume:23 year:1996 number:10/11 pages:0 http://dx.doi.org/10.1111/j.1440-1681.1996.tb01157.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 23 1996 10/11 0 |
| spelling |
10.1111/j.1440-1681.1996.tb01157.x doi (DE-627)NLEJ238597326 DE-627 ger DE-627 rakwb McLachlan, Andrew J. verfasserin aut SPARSE DRUG CONCENTRATION DATA ANALYSIS USING A POPULATION APPROACH: A VALUABLE TOOL IN CLINICAL PHARMACOLOGY Oxford, UK Blackwell Publishing Ltd 1996 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier 1. Drug concentration or pharmacological effect data collected from patients during therapy or as part of a Phase III or post-marketing study are generally sparse (i.e. one or a few observations per patient) in nature.2. The population approach to analysing sparse drug concentration data provides a valuable tool for obtaining information about the pharmacokinetics of drugs in special patient groups (neonates, aged or critically ill), the importance of drug interactions in the clinic (using routinely collected blood concentration data) and for conducting a ‘pharmacokinetic screen’ in patients during early phase efficacy trials.3. Using a population approach to analyse drug concentration-time data collected from patients during therapy or during an early phase investigation can complement information obtained from traditional pharmacokinetic/dynamic investigations to help gain a further insight into the factors that influence dosing guidelines. 2007 Blackwell Publishing Journal Backfiles 1879-2005 |2007|||||||||| cyclosporin In Clinical and experimental pharmacology and physiology Oxford [u.a.] : Wiley-Blackwell, 1974 23(1996), 10/11, Seite 0 Online-Ressource (DE-627)NLEJ243927150 (DE-600)2020033-X 1440-1681 nnns volume:23 year:1996 number:10/11 pages:0 http://dx.doi.org/10.1111/j.1440-1681.1996.tb01157.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 23 1996 10/11 0 |
| allfields_unstemmed |
10.1111/j.1440-1681.1996.tb01157.x doi (DE-627)NLEJ238597326 DE-627 ger DE-627 rakwb McLachlan, Andrew J. verfasserin aut SPARSE DRUG CONCENTRATION DATA ANALYSIS USING A POPULATION APPROACH: A VALUABLE TOOL IN CLINICAL PHARMACOLOGY Oxford, UK Blackwell Publishing Ltd 1996 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier 1. Drug concentration or pharmacological effect data collected from patients during therapy or as part of a Phase III or post-marketing study are generally sparse (i.e. one or a few observations per patient) in nature.2. The population approach to analysing sparse drug concentration data provides a valuable tool for obtaining information about the pharmacokinetics of drugs in special patient groups (neonates, aged or critically ill), the importance of drug interactions in the clinic (using routinely collected blood concentration data) and for conducting a ‘pharmacokinetic screen’ in patients during early phase efficacy trials.3. Using a population approach to analyse drug concentration-time data collected from patients during therapy or during an early phase investigation can complement information obtained from traditional pharmacokinetic/dynamic investigations to help gain a further insight into the factors that influence dosing guidelines. 2007 Blackwell Publishing Journal Backfiles 1879-2005 |2007|||||||||| cyclosporin In Clinical and experimental pharmacology and physiology Oxford [u.a.] : Wiley-Blackwell, 1974 23(1996), 10/11, Seite 0 Online-Ressource (DE-627)NLEJ243927150 (DE-600)2020033-X 1440-1681 nnns volume:23 year:1996 number:10/11 pages:0 http://dx.doi.org/10.1111/j.1440-1681.1996.tb01157.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 23 1996 10/11 0 |
| allfieldsGer |
10.1111/j.1440-1681.1996.tb01157.x doi (DE-627)NLEJ238597326 DE-627 ger DE-627 rakwb McLachlan, Andrew J. verfasserin aut SPARSE DRUG CONCENTRATION DATA ANALYSIS USING A POPULATION APPROACH: A VALUABLE TOOL IN CLINICAL PHARMACOLOGY Oxford, UK Blackwell Publishing Ltd 1996 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier 1. Drug concentration or pharmacological effect data collected from patients during therapy or as part of a Phase III or post-marketing study are generally sparse (i.e. one or a few observations per patient) in nature.2. The population approach to analysing sparse drug concentration data provides a valuable tool for obtaining information about the pharmacokinetics of drugs in special patient groups (neonates, aged or critically ill), the importance of drug interactions in the clinic (using routinely collected blood concentration data) and for conducting a ‘pharmacokinetic screen’ in patients during early phase efficacy trials.3. Using a population approach to analyse drug concentration-time data collected from patients during therapy or during an early phase investigation can complement information obtained from traditional pharmacokinetic/dynamic investigations to help gain a further insight into the factors that influence dosing guidelines. 2007 Blackwell Publishing Journal Backfiles 1879-2005 |2007|||||||||| cyclosporin In Clinical and experimental pharmacology and physiology Oxford [u.a.] : Wiley-Blackwell, 1974 23(1996), 10/11, Seite 0 Online-Ressource (DE-627)NLEJ243927150 (DE-600)2020033-X 1440-1681 nnns volume:23 year:1996 number:10/11 pages:0 http://dx.doi.org/10.1111/j.1440-1681.1996.tb01157.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 23 1996 10/11 0 |
| allfieldsSound |
10.1111/j.1440-1681.1996.tb01157.x doi (DE-627)NLEJ238597326 DE-627 ger DE-627 rakwb McLachlan, Andrew J. verfasserin aut SPARSE DRUG CONCENTRATION DATA ANALYSIS USING A POPULATION APPROACH: A VALUABLE TOOL IN CLINICAL PHARMACOLOGY Oxford, UK Blackwell Publishing Ltd 1996 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier 1. Drug concentration or pharmacological effect data collected from patients during therapy or as part of a Phase III or post-marketing study are generally sparse (i.e. one or a few observations per patient) in nature.2. The population approach to analysing sparse drug concentration data provides a valuable tool for obtaining information about the pharmacokinetics of drugs in special patient groups (neonates, aged or critically ill), the importance of drug interactions in the clinic (using routinely collected blood concentration data) and for conducting a ‘pharmacokinetic screen’ in patients during early phase efficacy trials.3. Using a population approach to analyse drug concentration-time data collected from patients during therapy or during an early phase investigation can complement information obtained from traditional pharmacokinetic/dynamic investigations to help gain a further insight into the factors that influence dosing guidelines. 2007 Blackwell Publishing Journal Backfiles 1879-2005 |2007|||||||||| cyclosporin In Clinical and experimental pharmacology and physiology Oxford [u.a.] : Wiley-Blackwell, 1974 23(1996), 10/11, Seite 0 Online-Ressource (DE-627)NLEJ243927150 (DE-600)2020033-X 1440-1681 nnns volume:23 year:1996 number:10/11 pages:0 http://dx.doi.org/10.1111/j.1440-1681.1996.tb01157.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 23 1996 10/11 0 |
| source |
In Clinical and experimental pharmacology and physiology 23(1996), 10/11, Seite 0 volume:23 year:1996 number:10/11 pages:0 |
| sourceStr |
In Clinical and experimental pharmacology and physiology 23(1996), 10/11, Seite 0 volume:23 year:1996 number:10/11 pages:0 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
cyclosporin |
| isfreeaccess_bool |
false |
| container_title |
Clinical and experimental pharmacology and physiology |
| authorswithroles_txt_mv |
McLachlan, Andrew J. @@aut@@ |
| publishDateDaySort_date |
1996-01-01T00:00:00Z |
| hierarchy_top_id |
NLEJ243927150 |
| id |
NLEJ238597326 |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ238597326</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230505184105.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">120417s1996 xx |||||o 00| ||und c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1111/j.1440-1681.1996.tb01157.x</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ238597326</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">McLachlan, Andrew J.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">SPARSE DRUG CONCENTRATION DATA ANALYSIS USING A POPULATION APPROACH: A VALUABLE TOOL IN CLINICAL PHARMACOLOGY</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Oxford, UK</subfield><subfield code="b">Blackwell Publishing Ltd</subfield><subfield code="c">1996</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">1. Drug concentration or pharmacological effect data collected from patients during therapy or as part of a Phase III or post-marketing study are generally sparse (i.e. one or a few observations per patient) in nature.2. The population approach to analysing sparse drug concentration data provides a valuable tool for obtaining information about the pharmacokinetics of drugs in special patient groups (neonates, aged or critically ill), the importance of drug interactions in the clinic (using routinely collected blood concentration data) and for conducting a ‘pharmacokinetic screen’ in patients during early phase efficacy trials.3. Using a population approach to analyse drug concentration-time data collected from patients during therapy or during an early phase investigation can complement information obtained from traditional pharmacokinetic/dynamic investigations to help gain a further insight into the factors that influence dosing guidelines.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="d">2007</subfield><subfield code="f">Blackwell Publishing Journal Backfiles 1879-2005</subfield><subfield code="7">|2007||||||||||</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">cyclosporin</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Clinical and experimental pharmacology and physiology</subfield><subfield code="d">Oxford [u.a.] : Wiley-Blackwell, 1974</subfield><subfield code="g">23(1996), 10/11, Seite 0</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)NLEJ243927150</subfield><subfield code="w">(DE-600)2020033-X</subfield><subfield code="x">1440-1681</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:23</subfield><subfield code="g">year:1996</subfield><subfield code="g">number:10/11</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1111/j.1440-1681.1996.tb01157.x</subfield><subfield code="q">text/html</subfield><subfield code="x">Verlag</subfield><subfield code="z">Deutschlandweit zugänglich</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-DJB</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">23</subfield><subfield code="j">1996</subfield><subfield code="e">10/11</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| series2 |
Blackwell Publishing Journal Backfiles 1879-2005 |
| author |
McLachlan, Andrew J. |
| spellingShingle |
McLachlan, Andrew J. misc cyclosporin SPARSE DRUG CONCENTRATION DATA ANALYSIS USING A POPULATION APPROACH: A VALUABLE TOOL IN CLINICAL PHARMACOLOGY |
| authorStr |
McLachlan, Andrew J. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)NLEJ243927150 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
NL |
| publishPlace |
Oxford, UK |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1440-1681 |
| topic_title |
SPARSE DRUG CONCENTRATION DATA ANALYSIS USING A POPULATION APPROACH: A VALUABLE TOOL IN CLINICAL PHARMACOLOGY cyclosporin |
| publisher |
Blackwell Publishing Ltd |
| publisherStr |
Blackwell Publishing Ltd |
| topic |
misc cyclosporin |
| topic_unstemmed |
misc cyclosporin |
| topic_browse |
misc cyclosporin |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| hierarchy_parent_title |
Clinical and experimental pharmacology and physiology |
| hierarchy_parent_id |
NLEJ243927150 |
| hierarchy_top_title |
Clinical and experimental pharmacology and physiology |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)NLEJ243927150 (DE-600)2020033-X |
| title |
SPARSE DRUG CONCENTRATION DATA ANALYSIS USING A POPULATION APPROACH: A VALUABLE TOOL IN CLINICAL PHARMACOLOGY |
| ctrlnum |
(DE-627)NLEJ238597326 |
| title_full |
SPARSE DRUG CONCENTRATION DATA ANALYSIS USING A POPULATION APPROACH: A VALUABLE TOOL IN CLINICAL PHARMACOLOGY |
| author_sort |
McLachlan, Andrew J. |
| journal |
Clinical and experimental pharmacology and physiology |
| journalStr |
Clinical and experimental pharmacology and physiology |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
1996 |
| contenttype_str_mv |
zzz |
| container_start_page |
0 |
| author_browse |
McLachlan, Andrew J. |
| container_volume |
23 |
| physical |
Online-Ressource |
| format_se |
Elektronische Aufsätze |
| author-letter |
McLachlan, Andrew J. |
| doi_str_mv |
10.1111/j.1440-1681.1996.tb01157.x |
| title_sort |
sparse drug concentration data analysis using a population approach: a valuable tool in clinical pharmacology |
| title_auth |
SPARSE DRUG CONCENTRATION DATA ANALYSIS USING A POPULATION APPROACH: A VALUABLE TOOL IN CLINICAL PHARMACOLOGY |
| abstract |
1. Drug concentration or pharmacological effect data collected from patients during therapy or as part of a Phase III or post-marketing study are generally sparse (i.e. one or a few observations per patient) in nature.2. The population approach to analysing sparse drug concentration data provides a valuable tool for obtaining information about the pharmacokinetics of drugs in special patient groups (neonates, aged or critically ill), the importance of drug interactions in the clinic (using routinely collected blood concentration data) and for conducting a ‘pharmacokinetic screen’ in patients during early phase efficacy trials.3. Using a population approach to analyse drug concentration-time data collected from patients during therapy or during an early phase investigation can complement information obtained from traditional pharmacokinetic/dynamic investigations to help gain a further insight into the factors that influence dosing guidelines. |
| abstractGer |
1. Drug concentration or pharmacological effect data collected from patients during therapy or as part of a Phase III or post-marketing study are generally sparse (i.e. one or a few observations per patient) in nature.2. The population approach to analysing sparse drug concentration data provides a valuable tool for obtaining information about the pharmacokinetics of drugs in special patient groups (neonates, aged or critically ill), the importance of drug interactions in the clinic (using routinely collected blood concentration data) and for conducting a ‘pharmacokinetic screen’ in patients during early phase efficacy trials.3. Using a population approach to analyse drug concentration-time data collected from patients during therapy or during an early phase investigation can complement information obtained from traditional pharmacokinetic/dynamic investigations to help gain a further insight into the factors that influence dosing guidelines. |
| abstract_unstemmed |
1. Drug concentration or pharmacological effect data collected from patients during therapy or as part of a Phase III or post-marketing study are generally sparse (i.e. one or a few observations per patient) in nature.2. The population approach to analysing sparse drug concentration data provides a valuable tool for obtaining information about the pharmacokinetics of drugs in special patient groups (neonates, aged or critically ill), the importance of drug interactions in the clinic (using routinely collected blood concentration data) and for conducting a ‘pharmacokinetic screen’ in patients during early phase efficacy trials.3. Using a population approach to analyse drug concentration-time data collected from patients during therapy or during an early phase investigation can complement information obtained from traditional pharmacokinetic/dynamic investigations to help gain a further insight into the factors that influence dosing guidelines. |
| collection_details |
GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE |
| container_issue |
10/11 |
| title_short |
SPARSE DRUG CONCENTRATION DATA ANALYSIS USING A POPULATION APPROACH: A VALUABLE TOOL IN CLINICAL PHARMACOLOGY |
| url |
http://dx.doi.org/10.1111/j.1440-1681.1996.tb01157.x |
| remote_bool |
true |
| ppnlink |
NLEJ243927150 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.1111/j.1440-1681.1996.tb01157.x |
| up_date |
2024-07-06T05:32:28.228Z |
| _version_ |
1803806518258171904 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ238597326</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230505184105.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">120417s1996 xx |||||o 00| ||und c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1111/j.1440-1681.1996.tb01157.x</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ238597326</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">McLachlan, Andrew J.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">SPARSE DRUG CONCENTRATION DATA ANALYSIS USING A POPULATION APPROACH: A VALUABLE TOOL IN CLINICAL PHARMACOLOGY</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Oxford, UK</subfield><subfield code="b">Blackwell Publishing Ltd</subfield><subfield code="c">1996</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">1. Drug concentration or pharmacological effect data collected from patients during therapy or as part of a Phase III or post-marketing study are generally sparse (i.e. one or a few observations per patient) in nature.2. The population approach to analysing sparse drug concentration data provides a valuable tool for obtaining information about the pharmacokinetics of drugs in special patient groups (neonates, aged or critically ill), the importance of drug interactions in the clinic (using routinely collected blood concentration data) and for conducting a ‘pharmacokinetic screen’ in patients during early phase efficacy trials.3. Using a population approach to analyse drug concentration-time data collected from patients during therapy or during an early phase investigation can complement information obtained from traditional pharmacokinetic/dynamic investigations to help gain a further insight into the factors that influence dosing guidelines.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="d">2007</subfield><subfield code="f">Blackwell Publishing Journal Backfiles 1879-2005</subfield><subfield code="7">|2007||||||||||</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">cyclosporin</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Clinical and experimental pharmacology and physiology</subfield><subfield code="d">Oxford [u.a.] : Wiley-Blackwell, 1974</subfield><subfield code="g">23(1996), 10/11, Seite 0</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)NLEJ243927150</subfield><subfield code="w">(DE-600)2020033-X</subfield><subfield code="x">1440-1681</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:23</subfield><subfield code="g">year:1996</subfield><subfield code="g">number:10/11</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1111/j.1440-1681.1996.tb01157.x</subfield><subfield code="q">text/html</subfield><subfield code="x">Verlag</subfield><subfield code="z">Deutschlandweit zugänglich</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-DJB</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">23</subfield><subfield code="j">1996</subfield><subfield code="e">10/11</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| score |
7.3982677 |